Pricing Log in Create free account

Abeona Therapeutics Inc. (ABEO) vs Inhibikase Therapeutics, Inc. (IKT)

Abeona Therapeutics Inc. and Inhibikase Therapeutics, Inc. are both Biotechnology companies. Abeona Therapeutics Inc. and Inhibikase Therapeutics, Inc. are of similar size ($265.9M and $255.4M). Abeona Therapeutics Inc. grew revenue faster over the last twelve months: 427.5% against 110.9%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −242.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Inhibikase Therapeutics, Inc. leads on 9 and Abeona Therapeutics Inc. on 8.

Valuation

Metric ABEO IKT Biotechnology median
P/E n/m n/m 8.50
P/S 9.68 1,105.73 9.71
P/B 1.96 1.88 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.60 495.30 9.21
Earnings yield (26.59%) (26.06%) (33.15%)
Free cash flow yield (32.48%) (14.80%) (25.50%)

Profitability

Metric ABEO IKT Biotechnology median
Gross margin 66.03% 100.00% 65.16%
Operating margin (322.59%) 0.00% 0.00%
Net margin (242.62%) 0.00% 0.00%
Free cash flow margin (314.53%) 0.00% 0.00%
Return on equity (43.13%) (51.96%) (56.36%)
Return on assets (29.54%) (48.04%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ABEO IKT Biotechnology median
Revenue growth (TTM) 427.47% 110.93% 6.02%
EPS growth (last fiscal year) 165.16% 57.76% 30.26%
Revenue growth, 5-year CAGR 14.19% (42.21%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABEO IKT Biotechnology median
Debt to equity 0.12 0.00 0.00
Current ratio 6.63 15.82 4.72
Net debt to EBITDA 2.00 3.44 0.96

Dividend

Metric ABEO IKT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ABEO IKT Biotechnology median
Market cap 265.90m 255.35m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack